US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi

US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi Leqembi won accelerated approval by the FDA in January based on its ability to remove sticky amyloid plaques from the brain. The panel on Friday considered Eisai's large confirmatory trial designed to show the drug benefited patients. https://ift.tt/0NfGR1m